2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
5
Recurrence
2
Esophageal Neoplasms
2
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
346
Cisplatin
240
Paclitaxel
208
Radiotherapy
207
Pemetrexed
190
Docetaxel
170
Gemcitabine
158
pembrolizumab
147
Erlotinib Hydrochloride
111
Magnetic Resonance Spectroscopy
102
Etoposide
99
Bevacizumab
96
Specimen Handling
84
Nivolumab
77
Radiosurgery
74
durvalumab
73
Blood Specimen Collection
65
Drug Therapy
61
osimertinib
56
Vinorelbine
54
Gefitinib
50
Surveys and Questionnaires
48
atezolizumab
45
Biopsy
43
Radiation
42
Irinotecan
42
Topotecan
39
Standard of Care
39
Cyclophosphamide
38
Surgical Procedures, Operative
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts